- Home
- MBLY vs EXAS Comparison
MBLY vs EXAS Comparison
Compare MBLY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBLY
- EXAS
- Stock Information
- Founded
- MBLY 1999
- EXAS 1995
- Country
- MBLY Israel
- EXAS United States
- Employees
- MBLY N/A
- EXAS N/A
- Industry
- MBLY Computer Software: Prepackaged Software
- EXAS Medical Specialities
- Sector
- MBLY Technology
- EXAS Health Care
- Exchange
- MBLY Nasdaq
- EXAS Nasdaq
- Market Cap
- MBLY 12.5B
- EXAS 10.7B
- IPO Year
- MBLY 2022
- EXAS N/A
- Fundamental
- Price
- MBLY $19.14
- EXAS $53.36
- Analyst Decision
- MBLY Buy
- EXAS Strong Buy
- Analyst Count
- MBLY 20
- EXAS 20
- Target Price
- MBLY $19.33
- EXAS $70.16
- AVG Volume (30 Days)
- MBLY 4.0M
- EXAS 2.8M
- Earning Date
- MBLY 07-31-2025
- EXAS 07-30-2025
- Dividend Yield
- MBLY N/A
- EXAS N/A
- EPS Growth
- MBLY N/A
- EXAS N/A
- EPS
- MBLY N/A
- EXAS N/A
- Revenue
- MBLY $1,853,000,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- MBLY $9.07
- EXAS $14.58
- Revenue Next Year
- MBLY $16.08
- EXAS $12.75
- P/E Ratio
- MBLY N/A
- EXAS N/A
- Revenue Growth
- MBLY N/A
- EXAS 11.57
- 52 Week Low
- MBLY $10.48
- EXAS $39.97
- 52 Week High
- MBLY $28.73
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- MBLY 67.69
- EXAS 49.61
- Support Level
- MBLY $17.20
- EXAS $52.60
- Resistance Level
- MBLY $19.38
- EXAS $55.09
- Average True Range (ATR)
- MBLY 0.89
- EXAS 2.09
- MACD
- MBLY 0.26
- EXAS -0.01
- Stochastic Oscillator
- MBLY 92.86
- EXAS 44.73
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.